Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
- PMID: 29176336
- DOI: 10.1097/01.NPR.0000526627.04268.80
Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
Abstract
Cardiovascular (CV) risk remains in some patients who are treated with statins. Evidence supports a role for triglycerides (TGs) in CV disease. TG-lowering agent outcomes studies have been inconsistent, but eicosapentaenoic acid significantly reduced coronary events in hypercholesterolemic patients who were treated with statins. Ongoing outcomes studies will clarify the role of TG-lowering treatments in CV risk reduction.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
